Dhan Chand: BOT/BAL shows potential to overcome immunological “cold” tumors
Dhan Chand, Vice President of Research at Agenus, shared a post on LinkedIn about recent paper by Breelyn Wilky et al., titled “Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas” published on Journal of Clinical Oncology.
Authors: Breelyn A. Wilky, Gary K. Schwartz, Michael S. Gordon, Anthony B. El-Khoueiry, Andrea J. Bullock, Brian Henick, Mark Agulnik, Arun Singh, Daruka Mahadevan, Justin Stebbing, Chloe Delepine, Dhan Chand, Manushak Avagyan, Wei Wu, Benny Johnson, Joseph E. Grossman, Steven O’Day, Jonathan C. Trent, Robin L. Jones, Apostolia M. Tsimberidou
“Thrilled to share our latest study published in Journal of Clinical Oncology! The combination of Botensilimab (multifunctional Fc-enhanced anti–CTLA-4) and Balstilimab (anti–PD-1) showed promising efficacy in heavily pretreated metastatic sarcomas, achieving a 19.2% objective response rate and durable outcomes.
Why this matters? Sarcomas are historically resistant to immunotherapy, with poor response rates to conventional checkpoint inhibitors. BOT/BAL shows potential to overcome immunological “cold” tumors and provide new hope for patients with limited treatment options.
Immense gratitude to the patients and their families who participated in this trial. And congratulations to Breelyn Wilky and the entire team!
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023